SiteOne Therapeutics
Is developing a new class of non-opioid treatments for hypersensitivity disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | $15.0m | Grant | |
| Total Funding | 000k | ||
Related Content
SiteOne Therapeutics is a biopharmaceutical company focused on developing innovative solutions for hypersensitivity disorders, including chronic cough and chronic pain. The company operates in the healthcare and pharmaceutical market, targeting patients suffering from these conditions. SiteOne Therapeutics employs a business model centered around research and development, leveraging advanced scientific expertise to create novel therapies. Revenue is generated through the commercialization of these therapies, either directly or through partnerships with larger pharmaceutical companies. The company’s team comprises leading experts from prestigious institutions such as Johns Hopkins University, Yale University, and the University of Arizona, ensuring a robust foundation for its scientific endeavors.
Keywords: biopharmaceutical, hypersensitivity, chronic cough, chronic pain, research, development, therapies, healthcare, pharmaceutical, commercialization.